Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01226875
Other study ID # 10-225
Secondary ID
Status Completed
Phase N/A
First received October 20, 2010
Last updated October 4, 2017
Start date January 2011
Est. completion date April 2017

Study information

Verified date October 2017
Source St. Michael's Hospital, Toronto
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Shockwave lithotripsy (SWL) is a safe, non-invasive treatment for renal calculi. During SWL energy is focused on in order to break kidney stones and this energy can be varied in size from a narrow (or small) focal zone to a wide (or large) focal zone. This is a multi-centered, randomized study comparing the single treatment success rates of narrow and wide focal zones during SWL.


Description:

Shock wave lithotripsy (SWL) is a safe and non-invasive treatment for kidney stones. The SWL machine that is currently in use has a unique feature: the focal zone or the energy that the SWL energy is focused on in order to break kidney stones can be varied in size from a narrow (or small) focal zone to a wide (or large) focal zone. Previous lithotripters have only offered one focal size that corresponded to a narrow range. The objective of this study is to compare the single-treatment success rates of narrow and wide focal zones for the shock wave lithotripsy of renal stones between 5 and 15 mm in greatest diameter, while maintaining a constant overall lithotripsy energy level. A wide focal zone may offer some trade-offs when compared with the traditional narrow focal zone: since the area being treated is larger, it is more likely that the stone will receive adequate energy as it moves with patient breathing during treatment, and less energy per cubic inch will be delivered to the kidney around the stone (which might lead to a lower degree of renal injury); on the other hand less energy per cubic inch will also be delivered to the stone, so that stone fragmentation might be inferior to that with a narrow focal zone. Thus, with this study we want to determine whether there is a significant difference in both stone fragmentation and in renal injury (as measured by the incidence of post-treatment renal hematoma or bruises, and by measuring urinary markers indicating the degree of renal cellular damage). Aside from the random choice of focal zone size, there will be no change to the standard of care for lithotripsy treatment. We predict that the narrow focal shock zone will result in superior stone fragmentation, with higher single-treatment stone free and success rates. However, we may identify a slight increased incidence in the rate of subcapsular renal hematoma and renal damage, as detected by urinary markers.


Recruitment information / eligibility

Status Completed
Enrollment 275
Est. completion date April 2017
Est. primary completion date November 2016
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Stone must be radiopaque on a KUB (kidney, ureter and bladder) radiograph, and located within the renal collecting system.

- Patients must have had a CT scan within the past 30 days.

- Stones must be solitary, between 5 and 15 mm in maximal diameter.

- Patient must consent to the trial and be willing to return to their respective lithotripsy unit at 2 weeks and 3 months for follow-up.

- Patients must be treated on the Storz Modulith SLX-F2 machine

Exclusion Criteria:

- More than one renal calculus on the treated side.

- Radiolucent stones (uric acid, indinavir) or cystine stones.

- Stone size < 5 mm and > 15 mm.

- Previous surgical intervention on upper tracts within past five years.

- Congenital anatomic anomalies of the kidney, ureters or bladder (such as calyceal diverticulum, horseshoe kidney, etc.)

- Patient currently taking an a-blocker (alfuzosin, terazosin, doxazosin, tamsulosin, prazosin), calcium channel blocker (verapamil, diltiazem, nifedipine, nicardipine, bepridil, mibefradil), or corticosteroids.

- Pregnancy.

- Age < 18 years.

- Active urinary tract infection.

- Patient exceed weight limit for SWL table (>500 lbs)

- Previous SWL treatment for this stone.

- Uncorrected coagulopathy

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
SWL: Shock Wave Lithotripsy Intervention
Shock wave lithotripsy (SWL) is the most common treatment modality for kidney stones. It is a safe and non-invasive treatment performed on patients under intravenous sedation (light anesthesia) on an out-patient basis, whereby shock waves are generated by a source external to the patient's body and are then propagated into the body and focused on a kidney stone. The unique quality of SWL is in its exploitation of shock wave focusing. The Storz lithotripter is an electromagnetic lithotripter with a unique design that allows for a dual focus system with the option of either a narrow (6x28 mm) or wide (9x50 mm) focal zone, depending on the clinical situation. This is the first lithotripter on the market to allow for two different focal zones for shock wave targeting.

Locations

Country Name City State
Canada St. Joseph's Hospital, University of Western Ontario London Ontario
Canada St. Michael's Hospital, University of Toronto, Toronto, Lithotripsy suite, 5th floor Cardinal Carter North Wing Toronto Ontario
Canada Vancouver General Hospital, Jim Pattison Pavilion G floor station 5 GI/GU Lithotripsy suite Vancouver British Columbia

Sponsors (4)

Lead Sponsor Collaborator
St. Michael's Hospital, Toronto University of British Columbia, University of Toronto, University of Western Ontario, Canada

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary SWL efficiency quotient comparison between narrow focus vs wide focus Comparison of single-treatment lithotripsy success rates at 2 and 12 weeks post-lithotripsy. Successful treatment will be defined as either stone-free status or presence of clinically insignificant asymptomatic residual fragments = 4 mm. SWL efficiency quotient for the treatment groups, as calculated by the standardized formula: % stone-free divided by (100 + % re-treated + % auxiliary procedures). 2 and 12 weeks
Secondary Incidence of perirenal hematomas Comparing the narrow and wide foci for the presence of perirenal hematomas post treatment on ultrasound. post treatment
Secondary Biomarkers for renal injury Comparisons of urinary markers for identifying renal injury day 0; day 1; 1 week
Secondary Time to stone passage Time it took to pass the stone for both arms will be compared for the 3 month follow up time. 12 weeks
Secondary Pain will be compared between narrow vs wide focus arms Visual analog pain scores will be compared between arms. day 0 (post treatment)
Secondary Complication rates Complication rates will be compared between narrow and wide focus treatment arms. 12 weeks
See also
  Status Clinical Trial Phase
Completed NCT02547805 - Evaluate the Effect of ALLN-177 in Reducing Urinary Oxalate in Patients With Secondary Hyperoxaluria and Kidney Stones Over 28 Days Phase 2
Completed NCT02579161 - Trial of Randomized Antibiotic Administration in Percutaneous Nephrolithotomy Phase 3
Completed NCT01187745 - Study to Look for Artifact on Computed Tomography (CT) Representing Kidney Stones N/A
Withdrawn NCT00875823 - International Registry for Primary Hyperoxaluria N/A
Completed NCT05519150 - Donors With Nephrolithiasis at the Time of Transplant Evaluation (DONATE). Long Term Follow-up.
Recruiting NCT02522689 - Comparison of Ultra-mini PCNL and Micro PCNL N/A
Recruiting NCT01514032 - Extracorporal Shockwave Lithotripsy Versus Retrograde Intrarenal Surgery for the Treatment of Kidney Stones N/A
Completed NCT00873054 - Percutaneous Nephrolithotomy Versus Extracorporeal Shock Wave Lithotripsy N/A
Completed NCT00765128 - Intravenous Ketorolac for Postoperative Pain in Percutaneous Nephrolithotomy Phase 4
Withdrawn NCT00583258 - A Randomized Study of Whether Alfuzosin(Xatral) Helps in the Passage of Kidney Stones N/A
Active, not recruiting NCT03630926 - Evaluation of the NV-VPAC1 Prostate Cancer (PCa) Urine Diagnostic Test in Subjects With Biopsy-confirmed Prostate Cancer, Benign Prostatic Hypertrophy, or Bladder/Kidney Stones.
Not yet recruiting NCT02214836 - Ultrasound Imaging of Kidney Stones and Lithotripsy N/A
Completed NCT03095885 - A Pilot Study of Oxalate Absorption in Secondary Hyperoxaluria N/A
Completed NCT01330940 - Effect of Diet Orange Soda on Urinary Lithogenicity N/A
Completed NCT01088555 - Effect of Sodium Thiosulfate on Urine Chemistries of Hypercalciuric Stone Formers N/A
Recruiting NCT00489723 - Is There is a Role of Prophylactic Therapy With Tamsulosin Before Extracorporeal Shock Wave Lithotripsy to Avoid Development of Steinstrasse ? N/A
Recruiting NCT05417568 - Oxalate-Driven Host Responses in Kidney Stone Disease N/A
Recruiting NCT02375295 - Struvite Stones Antibiotic Study Phase 4
Enrolling by invitation NCT02408211 - Preoperative Antibiotic PNL Study Phase 4
Withdrawn NCT01560091 - Differential Effect of Silodosin Versus Tamsulosin on Stone Clearance After Extra-corporeal Shock Wave Lithotripsy Phase 3